ivabradine has been researched along with Diabetes Mellitus in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SL; Hu, ZY; Li, B; Li, MH; Zuo, GF | 1 |
| Komajda, M | 1 |
| Borer, JS; Tardif, JC | 1 |
1 review(s) available for ivabradine and Diabetes Mellitus
| Article | Year |
|---|---|
Ivabradine.
Topics: Benzazepines; Cardiovascular Agents; Comorbidity; Diabetes Mellitus; Heart Failure; Hemodynamics; Hospitalization; Humans; Hypotension; Ivabradine; Pulmonary Disease, Chronic Obstructive; Quality of Life; Renal Insufficiency; Treatment Outcome | 2017 |
1 trial(s) available for ivabradine and Diabetes Mellitus
| Article | Year |
|---|---|
Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus.
Topics: Angina Pectoris; Benzazepines; Blood Glucose; Cyclic Nucleotide-Gated Cation Channels; Diabetes Mellitus; Double-Blind Method; Electrocardiography; Exercise Tolerance; Female; Follow-Up Studies; Humans; Ivabradine; Male; Middle Aged; Treatment Outcome | 2010 |
1 other study(ies) available for ivabradine and Diabetes Mellitus
| Article | Year |
|---|---|
I(f) current channel inhibitor (ivabradine) deserves cardioprotective effect via down-regulating the expression of matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic mice.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Benzazepines; Cardiotonic Agents; Caspase 3; Cells, Cultured; Diabetes Mellitus; Diabetic Cardiomyopathies; Disease Models, Animal; Down-Regulation; Ivabradine; Male; Matrix Metalloproteinase 2; Mice; Myocytes, Cardiac; NF-kappa B; Phosphorylation; Recovery of Function; Signal Transduction; Ventricular Function, Left | 2014 |